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Abstract 
On the basis of  the discussion in this paper, the process of  transferrin and iron (transferrin-bound iron and non transferr in-bound iron) 
uptake and transferrin release by reticulocytes are summarized iagrammatical ly.  A l though we were able to outline the pathways hown 
in the figure, there is still a long way to go before we achieve total understanding of the mechanisms of iron uptake. In addition, many 
important questions need to be answered. For example: what is the nature and properties of  the iron carrier on the membrane?  What  is the 
relationship between the iron carrier and transferrin receptor? Is the iron carrier system in membranes  of  cells from different t issues 
similar or different? And how does iron cross the membrane of  the endosomes after it is released from transferrin? All o f  these questions 
merit further investigation. 
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1. Introduction 
Iron is an essential element for all mammalian cells. 
Considerable research effort has been devoted to studying 
the mechanism of iron uptake by the cells and a consider- 
able amount of information has been obtained uring the 
last four decades, but some fundamental questions still 
remain unanswered. However, it is possible to assess the 
types of iron uptake mechanism used by the cells and to 
outline the process by which iron is transferred from serum 
to intracellular compounds. 
2. Transferrin-dependent iron uptake 
Transferrin-bound iron may be taken up by a variety of 
mechanisms. The best described involves receptor-media- 
ted endocytosis of transferrin. In addition, there is evi- 
dence for uptake by non-specific adsorptive ndocytosis, 
fluid-phase ndocytosis and by transmembrane reductase 
activity. 
2.1. Receptor-mediated endocytosis 
Most cells of vertebrate animals obtain iron from the 
plasma iron transport protein, transferrin [53]. The cellular 
process of transferrin-iron uptake by reticulocytes i  initi- 
ated with the binding of transferrin-iron to receptors on the 
cell membrane [57] then transferrin-iron e ters the cell by 
endocytosis of the receptor-transferrin-iron c mplex [53]. 
According to accumulated information the process of 
transferrin endocytosis can be distinguished into 6 main 
steps: binding, internalization (endocytosis), acidification, 
dissociation and reduction, translocation, and cytosolic 
transfer of iron into intracellular compounds uch as fer- 
ritin or haem. 
2.1.1. Binding 
The binding of transferrin to the extracellular portion of 
the receptor is the initial event in the cellular process of 
transferrin iron uptake by cells [40]. One transferrin 
molecule can bind to each subunit of the receptor. Binding 
of transferrin to the receptor is a simple physiochemical 
process independent of cell metabolism [100]. At 4°C, the 
binding reaction is a reversible process because internaliza- 
tion and processing of transferrin is negligible at this 
temperature. Near 37°C, however, the transferrin-iron-re- 
ceptor complex is rapidly endocytosed by cells [2]. At 
physiological pH (7.4) the affinity of the receptor for 
transferrin depends upon the degree of iron binding, the 
affinity constants (Ka) are approx. 1.1 × 108 M -~ for 
diferric transferrin, and 4.6 × 10 6 M-~ for apotransferrin 
in the rabbit reticulocytes [105]. Thus, under normal cir- 
cumstances, apotransferrin is unable to compete ffectively 
with diferric transferrin in binding to the receptor at the 
cell surface, only iron-containing transferrin molecules will 
be bound, although this may not be true in iron deficiency 
when transferrin saturation is reduced [12]. 
2.1.2. lnternal&ation 
The receptor-transferrin-iron c mplexes are clustered 
together and localized in clathrin-coated pits, which even- 
tually bud off to form coated vesicles, variously called 
endosomes or receptosomes [12]. It is probable that endo- 
cytosis of the receptors occurs independently of whether 
transferrin is bound or not [97], though contrary findings 
have been reported [43]. There is also controversy over 
whether phosphorylation is required for internalization, the 
evidence against his [19,107] being somewhat more con- 
vincing than the evidence in favour [51], although the 
situation may vary among different ypes of cells. 
In reticulocytes from many different ypes of vertebrate 
animals, the rate of endocytosis correlates closely with the 
rate of iron uptake under different experimental conditions 
[10,37,45-47]. A variety of reagents have been found to 
produce xactly proportional changes in the rates of trans- 
ferrin endocytosis and iron uptake [34,38]. Alteration in 
the pH and ionic strength of incubation solution produces 
an almost identical degree of changes in the rates of 
transferrin endocytosis and iron uptake by reticulocytes 
[62]. This evidence strongly supports the view that endocy- 
tosis of transferrin is a prerequisite for iron uptake. This is 
in part because the endosome formed by endocytosis pro- 
vides the acidic microenvironment which is required for 
iron-transferrin dissociation (see Fig. 1). 
2.1.3. Acidification 
Most of the membrane organelles in a typical eukary- 
otic cell belong to the elements of the exo- and endocytic 
pathways, referred to collectively as the vacuolar system 
including endosomes [52]. An important similarity among 
most of the organelles of the system is the presence of 
H+-ATP-ases responsible for generating an internal acidic 
environment. An ATP-dependent proton transport pump 
(H+-pump) has been found in a variety of subcellular 
orga[25,27,86,94,103,104]. In the process of uptake of 
transferrin-iron the vesicles lose their clathrin coat and 
fuse to form endosomes or the compartment of uncoupling 
of receptor from ligand (CURL) [17], in which the intrav- 
esicular pH is lowered to about 5-6 by means of an 
energy-dependent proton pump [12,104]. At this pH, the 
binding of iron to transferrin is weakened, leading to iron 
release from the protein. 
In a recent publication Nunez et al. [66] reported evi- 
dence that endocytic vesicles isolated from rabbit reticu- 
locytes contain intrinsic Ca(II)-pump activity which is 
dependent on ATP, activated by calmodulin and inhibited 
by vanadate and that acidification of endocytic vesicles 
inversely correlates with the Ca2+-pump activity. Acidifi- 
cation is inhibited by externally added Ca 2÷ and calmod- 
ulin, and activated by vanadate and EGTA. These results 
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suggest that intravesicular Ca 2+ can act as a modulator of 
endocytic vesicle acidification in reticulocytes. 
2.1.4. Dissociation and reduction 
It is widely accepted that the mechanism responsible for 
iron release after transferrin endocytosis acidification of 
the endocytic vesicle. Much evidence in favour of this 
hypothesis has been obtained. Paterson et al. [69] measured 
the pH in transferrin-containing vesicles of rabbit reticu- 
locytes and erythroid cells from the fetal rat liver and the 
result obtained was a pH of 5.4-5.5 which is similar to 
that reported for K562 cells [95]. Treatment of the cells 
with weak bases, metabolic inhibitors of H ÷ ionophores 
led to elevation of the vesicular pH and inhibition of iron 
uptake [69]. In the case of the bases this occurred without 
inhibition of transferrin endocytosis, and the degree of 
inhibition of iron uptake was directly related to the eleva- 
tion of intravesicular pH. In experiments on how chelators 
(2, 2' bipyridine and 1, 10-phenanthroline) inhibit iron 
uptake from transferrin [58], it was found that the iron-che- 
lator complexes were located in the vesicular fraction of 
the cells and were released from them by exocytosis, 
together with the apotransferrin. These results confirm that 
iron release from transferrin occurs within the vesicles. 
In many respects the transferrin uptake process in hepa- 
tocytes resembles that reported for reticulocytes [57]. This 
suggests that the mechanism of iron released from its 
transport protein may be similar, that is, protonation of the 
transferrin-iron resulting from acidification of the endocy- 
totic vesicles. The possibility is supported by the following 
evidence. The pH within rat liver endocytosic vesicles is 
5-5.5 [29] and clathrin-coated vesicles from rat liver con- 
tain an ATP-dependent proton transport system that acidi- 
fies the vesicle interior [94]. In addition, iron uptake by 
cultured rat hepatocytes [81] and the perfused rat liver is 
inhibited by weak bases which can elevate the pH of acidic 
intracellular compartments [60]. 
However, reduction in pH may not be the only factor 
[62] and it is likely that other mechanisms are also in- 
volved because one of the two iron-binding sites of human 
transferrin loses its iron only slowly at the pH level present 
in endosomes, yet iron is removed from both sites before 
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Fig. 1. Diagramatic representation f the steps involved in the uptake of iron by reticulocytes according to the mechanisms discussed in the text. (1) 
transferrin-bound iron (~)  binding to the transferrin receptor ( - -~)  on the membrane of reticulocytes; (2) internalization of the complex of 
transferrin-bound iron and receplor; (3) acidification of endosome by H+-ATP ases; (4) dissociation and reduction of iron; (5) translocation of iron across 
membrane of endosomes by a carrier ([])  or channel; (6) iron binding to cytosolic iron carders such as ATP (zx) or AMP (0 )  and transferring and 
binding to receptor for these complexes e.g., ATP-Fe (V) or AMP-Fe (U)  on the membrane of mitochondria and then enter into mitochondria for haem 
synthesis or to feritin for storage and (7) the receptor-transferrin complex (~)  returns to membrane. In addition, transferrin-free iron (• )  can be uptaken 
by reticulocytes by a carrier-mediated process which is dependent on ATP. 
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transferrin leaves the cell [37,69]. These mechanisms may 
include reduction of the iron [59], conformational change 
of transferrin due to interaction with its receptor and 
interaction with ATP or other cell metabolites. 
Bali et al. [4] recently reported a new role for the 
transferrin receptor in that the receptor can facilitate the 
release of iron from diferric transferrin at the low pH that 
prevails in endocytic vesicles. They found that, at pH 5.6, 
the receptor facilitates release of iron from transferrin, with 
an apparent initial rate of release from the receptor-trans- 
ferrin complex five times faster than from free transferrin 
[4]. The mechanism underlying the effect of the receptor 
on iron release from transferrin is not yet well understood. 
However, on the basis of some earlier research reports 
[1,3], Bali et al. proposed that at low pH, the transferrin 
receptor can force one or both lobes of transferrin into an 
open conformation, thereby facilitating release of iron. 
The investigations which led to the hypothesis that iron 
released from transferrin is in the Fe(II) oxidation state are 
based on results obtained by the use of colorimetric 
Fe(II)-chelators [14,90,92]. However, these reagents can 
facilitate reduction of iron. The results obtained in such 
experiments have therefore been criticized on thermody- 
namic grounds [93]. As a result, the conclusion that iron is 
released from transferrin as Fe(II) must be considered with 
caution. 
Pollack and Weaver [72] have observed that iron will be 
released from transferrin by hemolysates to which no 
chelate has been added. Zhan et al. [108] reported that the 
iron is released from transferrin by haemolysates and by 
haemoglobin and ATP, and that ADP and DPG can substi- 
tute for ATP, and NADH and NADPH can substitute for 
the haemoglobin. Hence it is possible that haemoglobin 
and ATP have a role in the process of iron release from 
transferrin. With respect to this question, it should be 
noted that ATP-mediated iron release from transferrin is a 
pH-dependent process and, at the pH of vesicles and the 
concentration of ATP found in the cytosol of reticulocytes, 
the rate of iron release may be rapid enough to account for 
the observed rate of uptake of transferrin-bound iron by 
cells [20]. However, it is unclear whether endocytosed 
transferrin is ever exposed to ATP and/or haemoglobin 
(or other reductants, cytosolic or membrane bound) in the 
cells [90,108] and further investigation is needed. 
transport of non-transferrin bound iron into a variety of 
cells, including intestinal mucosal cells, liver cells, reticu- 
locytes and transformed erythroid cells. 
2.1.6. 'Iron channel' hypothesis 
It is suggested that there is a formal structural and 
functional similarity between iron transport across the 
vesicular membrane by the transferrin-transferrin receptor 
system and the model for bacterial periplasmic transport 
[85]. According to this hypothesis, the released iron from 
transferrin and transferrin receptor complex, instead of 
entering the lumen of the vesicle, would travel directly 
through a channel formed in the vesicle membrane by the 
transferrin receptor tetramer and subsequently would be 
distributed to different intracellular compartments such as 
ferritin and haem proteins. 
A single transferrin molecule has four homologous but 
not identical domains which may each bind to the extracel- 
lular domain of one transferrin receptor subunit, generating 
a tetrameric omplex of 2 disulphide-linked dimers with a 
pseudo 4-fold symmetry axis perpendicular to the mem- 
brane. At the acid pH of vesicles the transferrin-transferrin 
receptor complex will undergo a conformational change 
and the four single hydrophobic transmembrane h lices of 
the receptor tetramer may generate a transmembrane chan- 
nel which may be a nonaqueous or a partially aqueous one 
for the iron to traverse. 
2.1.7. Carrier-mediated uptake 
The investigations of Morgan [61] and Egyed [21] have 
made important contributions to the mechanism by which 
iron released from transferrin enters the cytosol (see trans- 
ferrin-independent uptake). Their results have provided 
evidence for the presence of a high affinity, carrier-media- 
ted transport of Fe(II), or Fe(II) and Fe(III), into rabbit 
reticulocytes and suggest that Na ÷ is a modulator of 
carrier-mediated Fe(II) transport through the erythroid cell 
membrane [22]. Rat reticulocytes also contain a similar 
transport system [61]. 
At present, it is uncertain whether iron uptake is medi- 
ated by a carrier or channel. However, the temperature 
dependence, metal selectivity, and saturability of the iron 
uptake would support he mechanism of carrier-mediated 
uptake rather than the 'iron channel' hypothesis [89]. 
2.1.5. Translocation of  iron across vesicle membrane 
Translocation across cell membranes i an important 
step in the pathway of iron from serum transferrin to 
intracellular iron complexes uch as haem and ferritin. 
After iron is released from the transferrin-receptor c m- 
plex, the metal is still trapped in endocytic vesicles, there- 
fore it has to be transported through the membrane lining 
the vesicles. How the iron passes across this membrane 
into the cytosol is still an unresolved problem. One ap- 
proach to its investigation has been the study of the 
2.1.8. Cytosolic transfer of  iron into intracellular com- 
pounds 
The major identifiable ligand which binds iron in the 
low M r chelatable pool of the reticulocyte cytosol is ATP, 
and substantial amounts of AMP-iron complex are also 
present in the pool [98,99]. The existence of an ATP-iron 
complex is consistent with the many observations that 
have shown ATP to be effective at removing iron from 
transferrin [13,54-56,71]. Thus it seems plausible that 
ATP would continue to bind iron after the metal is re- 
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leased from transferrin [!)8] and transfer it to a mitochon- 
drial receptor from which the iron is incorporated into 
haem [99]. There appear to be two types of receptors for 
iron on the membrane ,f mitochondria: one that accepts 
iron only from ATP and which provides iron for haem 
synthesis with relatively low efficiency, and the other that 
accepts iron only from AMP (and not from ATP) and 
which provides iron for haem synthesis with relatively 
high efficiency. The major pathway by which iron is 
delivered for haem synthesis may be through hydrolysis of 
cytosolic ATP-iron to AMP-iron [99]. 
Other compounds which have been identified as ligands 
for iron include amino acids, polypeptides, proteins and 
uncharacterized growth factors [5,9,23,39,41,70]. How- 
ever, their roles, if any, as ligands for intracellular iron 
transport are not known. 
2.1.9. Intracellular pathway of the transferrin receptor- 
transferrin complex 
The interaction between transferrin and its receptor is 
strengthened rather than lost as a result of lowering the pH 
to 5-6, as occurs in endosomes. In many types of cells the 
endosome containing the receptor-transferrin complex 
passes to the Golgi, at which point its pathway interacts 
with that of the newly synthesized receptors [87], and is 
then returned to the cell membrane, with which it fuses. 
Internalized transferrin also returns to the plasma mem- 
brane with the vesicles. Microtubule-disrupting drugs can 
block delivery of endocytosed transferrin to the cytocenter, 
without affecting the return of transferrin to plasma mem- 
brane [80]. 
Having returned to the cell membrane, the receptor- 
transferrin complexes are now exposed to extracellular pH 
and the recycled transferrin molecules, which have lost 
their iron, are displaced by new iron-containing transferrin 
molecules from extracellular fluid, and the uptake process 
is repeated. Apotransferrin released from the receptors 
returns to the plasma or surrounding solution. 
In human and rat sera evidence was obtained for the 
existence of soluble transferrin receptors [7,36,44]. The 
serum receptor, a trunca~Eed form of tissue receptor, con- 
sists of a single polypeptide chain and its M r is about 
10000 less than that of the monomeric form of intact 
cell-bound receptors. The concentration of serum transfer- 
fin receptor in humans is 6 mg/l iter [24] as compared with 
3000 mg/l iter for transferrin, indicating that 1% of circu- 
lating transferrin may be complexed with soluble receptor. 
Although the binding of transferrin to its receptor fragment 
is likely to impair delivery of iron to cells, the proportion 
of transferrin complexed in this manner is too small to 
influence iron transport significantly. 
2.2. Low affinity adsorptive ndocytosis 
Not all cellular uptake of transferrin-bound iron de- 
pends exclusively on transferrin receptor-mediated pro- 
cesses. For example, the hepatocyte may also exploit 
non-specific (non-saturable) low affinity binding of trans- 
ferrin to cell membrane followed by endocytotic internal- 
ization to an acidifiable compartment where iron is re- 
leased [60,68]. This non-specific process is believed to be 
independent of the transferrin receptor and may be the 
principal mechanism operating at a physiological transfer- 
rin concentration. The rate of iron uptake by this process 
by cultured rat hepatocytes i quantitatively comparable 
with the uptake of iron by rat liver in vivo [28], and the 
iron is largely incorporated into ferritin, suggesting that it 
represents a physiological phenomenon. 
2.3. Fluid-phase ndocytosis 
Fluid-phase endocytosis is also involved in the non- 
specific (non-saturable) uptake of iron by cultured rat 
hepatcytes, although it is not a major mechanism [60]. 
Page et al. [68] determined the rate of fluid endocytosis of 
cultured hepatocytes from the cellular uptake of ,z. I-poly- 
vinylpyrrolidone during the 24- to 48-h period after com- 
mencement of culture. The mean value obtained was 68 
ml .g  DNA ' .  24 h ~ equivalent to approximately 0.71 
ml. 100 g cells -~ • h ' or to 0.93 nmol transferrin 100 g 
ce l l - ' -h -~ at a transferrin concentration of 1.33 /zmoi, 
which is similar to that of rat hepatocytes in suspension 
[67] or that of the rat liver in vivo [64]. Transferrin uptake 
at this rate could account for only about 5% of the 
measured rate of iron uptake by cells cultured in the 
presence of diferric transferrin at this concentration [68]. 
2.4. Transmembrane-reductase 
Several models propose that iron is released from trans- 
ferrin by a reductive process (direct reduction) at the cell 
surface [14,91,92]. Recently the existence of a distinct 
NADH diferric transferrin reductase on the plasma mem- 
brane has been suggested [90]. 
Thorstensen and Romslo [92] reported that the uptake of 
iron from transferrin by isolated rat hepatocytes varies in 
parallel with plasma membrane NADH:ferricyanide oxido- 
reductase activity, and is inhibited by ferricyanide, ferric, 
ferrous iron chelators and divalent ransition metal cations, 
it also depends on calcium ions but not endosomal acidifi- 
cation or endocytosis of transferrin. A model for the 
uptake of iron from transferrin by hepatocytes derived 
from these results and others was presented [92]. Accord- 
ing to this, transferrin binds to its receptor in close proxim- 
ity to the NADH:ferricyanide oxidoreductase. Concert pro- 
ton and electron fluxes destabilize the transferrin-iron bond 
and reduces iron which is then trapped by appropriate 
plasma membrane f rrous iron ligands. In subsequent s eps, 
ferrous iron is internalized and taken up by the various 
biosynthetic pathways, whereas iron-depleted transferrin is 
displaced from the receptor by diferric transferrin. 
Other studies have suggested similar conclusions. Dan- 
cis et al. [18] provided genetic evidence that ferric reduc- 
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tase on the membrane is required for iron uptake in 
Saccharomyces cerevisiae. A plasma membrane reductase 
activity able to reduce ferric iron has been observed in 
many types of cells, such as some bacterial strains, fungi, 
plant and animal cells [8,16,48,65,90]. However, it has also 
been reported that ferricyanide reductase and transferrin- 
stimulated NADH oxidase activities are not linked to 
release of iron from transferrin [93]. Thus further studies of 
the mechanism are needed. 
3. Transferrin-independent iron uptake 
Transferrin-mediated iron delivery has generally been 
considered to be the only or main route for cellular iron 
accumulation. A number of studies, however, suggest that 
non-transferrin-bound iron (or transferrin-free iron) can 
enter cells by different mechanisms, uch as carrier-media- 
ted uptake, simple diffusion, and lipid peroxidation- 
mediated iron uptake. 
3.1. Carrier mediated transferrin-free iron uptake 
Several groups of researchers have reported evidence 
for carrier-mediated binding or transport of iron by intesti- 
nal mucosal cell membrane [15,63] [79,83,84,88], liver 
cells [11,30,82,101,102], cultured transformed cells 
[6,42,89] and ret iculocytes [10 ,21 ,22 ,61 ,73-  
75,77,78,96,107]. Thus it is possible that carrier-mediated 
transport is a common mechanism of iron uptake in differ- 
ent types of cells. 
3.1.1. Intestinal mucosal cells 
The microvillar surface of intestinal cells normally takes 
up iron in a transferrin-free form [83]. Several studies on 
the uptake of iron by intestinal mucosal cells have demon- 
strated saturable iron binding to and/or transport across 
the cellular membrane, suggesting the presence of a car- 
der-mediated mechanism in the process of iron uptake 
[15,63,83]. 
A study on Fe(III)-citrate and Fe(II)-ascorbate uptake 
by purified intestinal brush-border membrane vesicles from 
normal (iron-replete) and iron-deficient mice [63] provided 
evidence that Fe(II) was transported into the vesicles by a 
membrane carrier-mediated process. This was obtained by 
observing saturation kinetics under conditions of isotope 
exchange at equilibrium in mice rendered iron-deficient, 
but not in iron-replete mice. The uptake of Fe(II) by the 
brush border membrane appears to be a two-fold process 
[63]. The first step is the binding of Fe(II) to apparent high 
affinity binding sites on the membrane surface and trans- 
port of Fe(II) across the membrane by a carrier-mediated 
process. The second step in vitro is the subsequent binding 
(chelation) of the iron on the inside of the membrane in a 
reversible process in the presence of a suitable chelating 
agent (EDTA, DFO). In vivo the second step is likely to 
show apparent irreversibility as iron is further metabolized 
by intracellular mechanisms and is not available for trans- 
port through the luminal surface of the mucosal cell. 
Saturation kinetics in Fe(II) uptake by rat brush-border 
membrane vesicles occurs over the range 0 -2  p,M Fe(II), 
by rabbit brush-border membrane vesicles over the concen- 
tration range 45-450/zM [15], and by iron-deficient mouse 
membrane up to 17/zM Fe(II) [63]. The uptake of iron can 
be competitively inhibited by some divalent cations such 
as Co 2+ and Mn 2+. Co 2+ gives an approximately 50% 
inhibition at Co2+: Fe z+ ratio of 10, and Mn 2+ shows 
similar inhibition to Co 2÷ [83]. 
3.1.2. Liver cells 
The liver plays a central role in iron metabolism both in 
normal individuals and in iron-overload individuals. Nor- 
mally, about 99% of the iron in plasma is bound to 
transferrin, while the remainder (less than 1%) circulates 
as low molecular weight complexes or in association with 
other serum proteins such as albumin [50]. However, in 
iron-overload states, the proportion of non-transferrin- 
bound iron is increased and may be as high as 35% in 
certain patient groups. The non transferrin-bound plasma 
iron is rapidly cleared from the circulation by the liver 
[ll,101]. 
Some experimental studies on the mechanism by which 
non-transferrin-bound iron is transported into liver cells 
have been published. Zimelman et al. [109] have reported 
rapid clearance of Fe(II)-citrate by the recirculating per- 
fused rat liver. Grohlich et al. [31], using iron concentra- 
tions considerably above those that occur in plasma, have 
found evidence for saturable uptake of Fe(III) by suspen- 
sions of rat hepatocytes. Brissot et al. [l l] examined the 
hepatic removal process for various iron complexes in the 
single-pass perfused rat liver and reported that hepatic 
uptake of both Fe(II) and Fe(III) from ultrafiltered human 
serum was highly efficient and effectively irreversible, and 
similar high efficiencies were seen for iron complexed to 
specific physiological and non-physiological coordinators, 
including histidine, citrate, fructose, oxalate, glutamate and 
tricine [11]. The transport mechanism is a carrier-mediated 
process, as evidenced by (1) saturation kinetics: hepatic 
removal from Krebs-tricine buffer is saturable with similar 
kinetic parameters for Fe(II) and Fe(III) (apparent K m 
14-22 /zM: Vma x 24-38 nmol min -1 g liver -1) [11]; (2) 
competitive inhibition by other transition metal ions: Zn 2+, 
CO 2+ and Mg 2+ reversibly inhibits Fe(II) uptake and the 
inhibition by Zn 2+ was shown to be competitive [101]; and 
(3) temperature-dependent (E= 14.3 Kcal/mol) [101]. 
These results suggest hat a membrane cartier system is 
involved in the uptake of non-transferrin-bound iron by the 
liver. In addition, they reported that the uptake process is 
not regulated by the iron status of the animal, is strongly 
calcium-dependent and is relatively insensitive to in- 
hibitors of cellular energy metabolism. 
As a result of monitoring hepatocyte membrane poten- 
tial during iron uptake, it was concluded that the carrier- 
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mediated uptake occurs by an electrogenic mechanism in 
which there is net movement of positive charge into the 
cell [102]. Hepatic accumulation of other transition metal 
ions such as Cu 2+, Zn 2÷ and Mg 2÷ may be driven by 
similar forces since these ions may share a common carrier 
with iron [11,101]. 
3.1.3. Cultured cells 
Transferrin-independent irontransport has been demon- 
strated in a wide variety of cultured cells such as HeLa, 
human skin fibroblasts, Chinese hamster ovary cells [42,89] 
and L1210 cell [6]. 
The characteristics of the non-transferrin-bound iron 
uptake system in HeLa cells are similar to the transport 
system described for rat liver. Iron uptake by this system 
in both hepatocytes and HeLa cells is saturable, Ca2+-de - 
pendent and inhibited by some divalent cations. Sturrock et 
al. [89] reported that Hela cells incubated in a serum-free 
medium accumulated 59Fe when incubated with either 
59Fe-nitrilotriacetate, 59Fecitrate or 59Fe dissolved in 
Tricine ascorbate, and the accumulation of iron was time-, 
concentration-, and Ca2+-dependent and exhibited sat- 
urable kinetics. There was little discrimination between 
Fe(II) and Fe(III). After exposure of cells to non-transfer- 
rin-bound iron at 37°C, most of the cell-associated radioac- 
tivity was recovered in haem and ferritin, demonstrating 
that iron gained access to intracellular compartments and 
was not simply adsorbed to the cell surface. The uptake of 
iron could be partially blocked by Cu e+ in a dose-depen- 
dent manner, and other transition metals such as Zn 2+, 
Cd 2+, and Mn 2+ were able to inhibit the uptake by 
different degrees. The metal selectivity plus the tempera- 
ture dependence and saturability of uptake strongly suggest 
that a carrier-mediated mechanism was involved in the 
accumulation of non-transferrin-bound iron in Hela cells 
[89]. 
The accumulation of ~°'~Cd by Hela cells was inhibited 
by incubation of the cells 'with non-transferrin-bound iron, 
Cu 2+, or Mn 2+, and the extent of inhibition was concentra- 
tion- and metal-dependent [89]. This suggests that the 
transport system that mediates iron uptake also mediates 
the accumulation of other metals such as Cd 2+, suggesting 
the presence of a transport system for transition metals in 
Hela cells. The transport system in Hela cells for the 
uptake of iron and Cd 2÷, which are not affected by 
verapamil (Ca 2+ channel blockers), may be different with 
the Cd 2+ uptake system in neuronal tissue or in cell types 
derived from neuronal tissues which can be partially inhib- 
ited by verapamil [35] and is regulated ifferently than the 
transferrin-mediated pathway [42]. The activity of the 
transport system in Hela cells was unaffected by changes 
in cellular growth rate, induction of DNA synthesis and 
cell division, or depletion of cellular iron [42]. 
In the absence of transferrin, it has been demonstrated 
that L1210 leukemic cells are still able to take up iron 
from the medium by a saturable mechanism and use it to 
stimulate DNA synthesis [6]. The K m for this transport 
system is 30/xM and the uptake is abolished at 4°C. These 
results suggest hat the uptake of transferrin-free iron in 
L1210 cell is mediated by an iron carrier. 
3.1.4. Reticulocytes 
Reticulocytes show very active uptake of transferrin- 
bound iron. During the process the iron is dissociated from 
transferrin. How this iron passes across the vesicular mem- 
brane into the cytosol is very poorly understood. 
Young and Gomperts [106] reported that A23 187 and 
certain other carboxylate ionophores were capable of trans- 
ferring Fe(II) but not Fe(III) across phospholipid bilayers 
(liposomes) and the red cell membrane. Ponka et al. [73] 
examined whether reticulocytes depleted of transferrin 
might incorporate 59Fe from 59Fe-labelled pyridoxal isoni- 
cotinoyl hydrazone (PIH) and found that transferrin-de- 
pleted reticulocytes showed a time-, temperature- and con- 
centration-dependent incorporation of 59Fe when incubated 
with 20-200 /zM 59Fe-PIH. A similar conclusion was 
reached for iron utilization by reticulocytes from several 
other ferric aroyl hydrazones [74,75]. Iron complexes of 
DL-penicillamine, citrate and six different aroyl hydrazones 
may be utilized by transferrin-depleted r ticulocytes for 
hemoglobin synthesis without he involvement of transfer- 
rin and the transferrin receptor [26]. All of the above 
results demonstrated that non-transferrin-bound iron could 
be taken up by reticulocyes. However, it should be noted 
that all of these studies involved the use of iron bound by 
complexing agents which may act as artificial vehicles for 
iron transport into cells, so that the results are difficult to 
interpret with respect o the normal transport process. 
Morgan [61] investigated the transport of non-transfer- 
rin-bound iron into rabbit reticulocytes by incubating the 
cells in 0.27 M sucrose with iron labelled with 59Fe and 
reported that the rabbit reticulocyte can transport transfer- 
fin-free iron into the cytosol and incorporate it into haem. 
The membrane transport process could be divided into two 
components: aturable or specific uptake and non-saturable 
or non-specific uptake. The two types of transport had 
different features. Saturable uptake displayed saturation 
kinetics with a K m value of approx. 0.2 izM and was 
competitively inhibited by other divalent ransition metal 
ions such as Co 2+, Mn 2+, Ni 2+, and Zn 2+, while the other 
process was non-saturable and increased linearly with in- 
creasing iron concentration [61]. Saturable uptake ceased 
when the reticulocytes matured into erythrocytes and there 
was a close correlation between the rate of iron uptake and 
the reticulocyte count. This uptake was also pH-and 
temperature-sensitive, th  pH optimum being 6.5. The 
activation energy for iron transport into cytosol was about 
80 kJ/mol. Fe(II) and Fe(III) both could be transported 
into the cytosol and utilized for haem synthesis. It was 
concluded from these results that the transport of non- 
transferrin-bound iron into the cytosol occurs in part via a 
carrier-mediated process. Subsequent s udies [76,77] from 
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the laboratory support he conclusion, and report that the 
uptake of transferrin-free iron by reticulocytes i depen- 
dent on the cellular concentration f ATP and that transfer- 
fin-free iron crosses the cell membrane by an active car- 
rier-mediated process. Research in vivo and in vitro [78] 
shows that membrane carrier for iron and transferrin-recep- 
tor are lost at the same rate during reticulocytes matura- 
tion. 
A similar conclusion was reached by Egyed [21]. How- 
ever, the model system used by Egyed involved the use of 
Fe(II) complexed by ascorbate. In contrast with other 
studies of different cells mentioned earlier and Egyed's 
study, in the experimental system used by Morgan, no 
carrying or reducing agent was used other than sucrose 
which served as the iron-stabilizing agent [61]. Sucrose is 
unable to enter reticulocytes [61] and acts only as a weak 
iron chelator for maintaining the iron in solution in a form 
which can be assimilated by the cells. Hence, it is likely 
that the iron was transported into the cells in the ionic 
state, although the possibility of participation of iron chela- 
tors derived from cells, such as ATP, cannot be entirely 
excluded. 
3.2. Lipid peroxidation-mediated ironuptake 
A physiological role of lipid peroxidation i membrane 
transport of iron has been postulated, based on the follow- 
ing experimental results. (1) Fe(II) can pass rapidly through 
the membrane of gut microvillus membrane vesicles while 
Fe(III) only binds to the membrane. (2) Ferrous ascorbate 
and ferric nitrilotriacetate are able to induce lipid peroxida- 
tion of vesicle in a dose-dependent way. (3) Lipid per- 
oxidation is inhibited by catalase, thiourea, vitamin E and 
desferrioxamine (DFO). 
To test this hypothesis, Marx et al. [49] studied the 
relation between lipid peroxidation and the iron uptake by 
rabbit small intestinal microvillus membrane vesicles, and 
the inhibiting effects of scavengers of toxic oxygen species 
(free radicals) on iron uptake. They found that iron uptake 
from 5 #M iron solutions by the microvillus vesicles was 
5.67 nmol/mg protein (Fe(II) and Fe(III)) and uptake from 
200 /zM iron solution was 1.84 nmol/mg protein. Prein- 
cubation of the vesicles with scavengers of free radicals 
gave much lower results. When the vesicles were pre-in- 
cubated with DFO (0.8 mM), superoxide dismutase (0.2 
mg/ml), catalase (0.3 mg/ml), and vitamin E (2.5 mg/ml) 
for 15 min, iron uptake from 5 /zM iron solution by the 
microvillus vesicles was only 0.16, 1.83, 0.65, and 1.03 
nmol/mg protein, and from 200 /zM iron solution only 
0.59, 1.34, 0.90, and 0.96 nmol/mg protein, respectively, 
all of which were much smaller than that in the absence of 
scavengers. It was concluded from their results that iron 
may initiate its own membrane transport by lipid peroxida- 
tion. 
Biological membranes including the membrane of rab- 
bit reticulocytes are rich in unsaturated fatty acids which 
are susceptible to peroxidative attack and iron itself is a 
promotor of free radical reaction and lipid peroxidation 
[32,33]. Also the combination of iron and ascorbate can be 
a potent oxidizing system, promoting lipid peroxidation. 
Therefore lipid peroxidation should be theoretically con- 
sidered as a possible source of artefacts when biological 
membrane, iron and reductant such as ascorbate are pre- 
sent in an experimental system. 
However, the presence of 600 IU/ml superoxide dis- 
mutase (free radical scavenger) had no effect on iron 
uptake by rabbit reticulocytes and there was no noticeable 
effect of presence or absence of oxygen on iron uptake by 
the cells [21]. Morgan and Qian (unpublished data) investi- 
gated the effect of lipid peroxidation on transferrin-free 
iron uptake by rabbit reticulocytes to determine whether 
the experimental system used by Morgan [61] is valid for 
studying membrane transport mechanisms of transferrin- 
free iron. The results show that there is no increase in 
thiobarbituric acid reactive products as the iron concentra- 
tion (< 10 /xM) is increased, and that free radical scav- 
engers (Butylated hydroxyanisol 5-10 /zm, butylated hy- 
droxytoluene 10-25 /zm, Superoxide dismutase 600 
IU/ml, a-tocopherol 10-100 /zm and propyl gallate 3250 
/zg/ml) and producers (t-butyl hydroperoxide 10-25 /zm, 
Cumene hydroperoxide 2-10 /zm) have no noticeable 
effect on iron uptake except 50 /xm of aluminum carbon- 
ate (producer) which decreases (not increases) iron uptake 
to a greater degree, the values of iron uptake into haem 
and cytosol being 37% and 27% of the control values 
respectively. The above results suggest hat the uptake of 
iron by rabbit reticulocytes i not a consequence of free 
radical production. Thus, it is possible that the role of lipid 
peroxidation i iron uptake by cells from different issues 
are different and further studies of lipid peroxidation- 
mediated uptake by different issue cells are needed. 
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